<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2020.107184</article-id><article-id pub-id-type="publisher-id">ACM-36416</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20200700000_14117805.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  706例胸段食管癌患者术后无进展生存状况分析
  Analysis of Post-Esophagectomy Progression Free Survival in 706 Patients with Thoracic Esophageal Carcinoma
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>刘</surname><given-names>鸿章</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>陈</surname><given-names>新</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>何</surname><given-names>明</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>高</surname><given-names>占杰</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>李</surname><given-names>丹</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>李</surname><given-names>欣慧</given-names></name><xref ref-type="aff" rid="aff5"><sup>5</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>张</surname><given-names>香梅</given-names></name><xref ref-type="aff" rid="aff5"><sup>5</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>赵</surname><given-names>继东</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>晏</surname><given-names>峰</given-names></name><xref ref-type="aff" rid="aff6"><sup>6</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff5"><addr-line>河北医科大学第四医院科研中心，河北 石家庄</addr-line></aff><aff id="aff6"><addr-line>河北省沙河市人民医院外科，河北 沙河</addr-line></aff><aff id="aff2"><addr-line>河北省保定市第一中心医院，普通外四科，河北 保定</addr-line></aff><aff id="aff4"><addr-line>河北省石家庄市井陉县医院胸外科，河北 石家庄</addr-line></aff><aff id="aff3"><addr-line>河北医科大学第四医院胸外科，河北 石家庄</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>01</day><month>07</month><year>2020</year></pub-date><volume>10</volume><issue>07</issue><fpage>1199</fpage><lpage>1204</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    目的：研究真实世界中胸段食管癌的复发特点及患者对辅助治疗的反应。方法：回顾性收集我院2008年1月至2015年12月就诊的食管癌术后复发患者，分析患者TNM分期、病理类型、淋巴结转移及辅助治疗对术后无进展生存的影响。结果：706例患者中鳞癌所占比例为93.06%，1年、3年、5年术后无进展生存率为52.1%、14.4%、5.2%，1年、3年、5年总生存率为63.9%、39.9%、14.9%。不同病理类型患者的中位术后无进展生存时间，鳞癌患者为13个月，腺癌14.5个月，小细胞癌12个月，其它14个月，各组间无统计学差异。657例鳞癌患者中，不同pTNM分期患者的术后无进展生存时间为3.41~26.4个月，3年术后无进展生存率为4.21%~44.5%，5年术后无进展生存率为0%~26.7%，术后无进展生存趋势与pTNM分期呈负相关。I期至IIb期患者接受辅助化疗对术后无进展生存期影响不明显(I-IIa期，p = 0.81；IIb期，p = 0.61)；III~IV期患者接受辅助化疗可提供术后无进展生存时间(IIIa期，p = 0.0009；IIIb期，p = 0.00001；IIIc-IV期，p = 0.047)，差异有统计学意义。结论：胸部食管癌术后不同分期患者的术后无进展生存特点不同、术后辅助化疗的结果也不同。我们的数据显示，早期食管癌微转移、精准判断术后辅助治疗的获益人群及发现新的有效辅助治疗手段应该成为食管癌诊治的研究热点。
    Objective: To study the characteristics of post-operative recurrence and the adjuvant therapy response of patients with thoracic esophageal carcinoma in the real world. Methods: Patients with recurrent of esophageal cancer were retrospectively collected from January 2008 to December 2015 in our hospital. The influence of pathological TNM stage, pathological type, lymph node metastasis and adjuvant treatment on progression free survival (PFS) was analyzed. Results: Of the 706 patients eligible for this study, 657 (93.06%) patients as esophageal squamous cell carcinoma (ESCC), the 1-, 3- and 5-year PFS rate were 52.1%, 14.4% and 5.2%, and the 1-, 3- and 5-year overall survival rate were 63.9%, 39.9% and 14.9%. The median postoperative progression free survival time has no significant difference in patients with different pathological types (13 months/ ESCC, 14.5 months/adenocarcinoma, 12 months/small cell carcinoma, 14 months/others). With different pathological TNM stages of ESCC patients, the time of PFS were 3.41 - 26.4 months, 3-year PFS rate was 4.21% - 44.5%, 5-year PFS rate was 0% - 26.7%. Adjuvant chemotherapy was significantly improved median PFS time in III stage patients with ESCC (IIIa, p = 0.0009; IIIb, p = 0.00001; IIIc, p = 0.047), but not in patients with I - II stages. Conclusion: The characteristics of PFS are different in patients with different stages of thoracic esophageal cancer, and the outcome of postoperative adjuvant chemotherapy are different too. From our data, micrometastasis of early esophageal cancer, accurate judgment of the beneficiaries of adjuvant therapy and discovery of new therapy should be the clinical research focus of esophageal cancer. 
  
 
</p></abstract><kwd-group><kwd>食管癌，食管癌切除术，术后复发，无进展生存，辅助化疗, Esophageal Carcinoma</kwd><kwd> Esophagectomy</kwd><kwd> Postoperative Recurrence</kwd><kwd> Progression Free Survival</kwd><kwd> Adjuvant Chemotherapy</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>706例胸段食管癌患者术后无进展生存状况 分析<sup> </sup></title><p>刘鸿章<sup>1</sup>，陈新<sup>2</sup>，何明<sup>2</sup>，高占杰<sup>2</sup>，李丹<sup>3</sup>，李欣慧<sup>4</sup>，张香梅<sup>4</sup>，赵继东<sup>2*</sup>，晏峰<sup>5*</sup></p><p><sup>1</sup>河北省保定市第一中心医院，普通外四科，河北 保定</p><p><sup>2</sup>河北医科大学第四医院胸外科，河北 石家庄</p><p><sup>3</sup>河北省石家庄市井陉县医院胸外科，河北 石家庄</p><p><sup>4</sup>河北医科大学第四医院科研中心，河北 石家庄</p><p><sup>5</sup>河北省沙河市人民医院外科，河北 沙河</p><disp-formula id="hanspub.36416-formula3"><graphic xlink:href="//html.hanspub.org/file/10-1571381x5_hanspub.png"  xlink:type="simple"/></disp-formula><p>收稿日期：2020年6月5日；录用日期：2020年6月30日；发布日期：2020年7月7日</p><disp-formula id="hanspub.36416-formula4"><graphic xlink:href="//html.hanspub.org/file/10-1571381x6_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>目的：研究真实世界中胸段食管癌的复发特点及患者对辅助治疗的反应。方法：回顾性收集我院2008年1月至2015年12月就诊的食管癌术后复发患者，分析患者TNM分期、病理类型、淋巴结转移及辅助治疗对术后无进展生存的影响。结果：706例患者中鳞癌所占比例为93.06%，1年、3年、5年术后无进展生存率为52.1%、14.4%、5.2%，1年、3年、5年总生存率为63.9%、39.9%、14.9%。不同病理类型患者的中位术后无进展生存时间，鳞癌患者为13个月，腺癌14.5个月，小细胞癌12个月，其它14个月，各组间无统计学差异。657例鳞癌患者中，不同pTNM分期患者的术后无进展生存时间为3.41~26.4个月，3年术后无进展生存率为4.21%~44.5%，5年术后无进展生存率为0%~26.7%，术后无进展生存趋势与pTNM分期呈负相关。I期至IIb期患者接受辅助化疗对术后无进展生存期影响不明显(I-IIa期，p = 0.81；IIb期，p = 0.61)；III~IV期患者接受辅助化疗可提供术后无进展生存时间(IIIa期，p = 0.0009；IIIb期，p = 0.00001；IIIc-IV期，p = 0.047)，差异有统计学意义。结论：胸部食管癌术后不同分期患者的术后无进展生存特点不同、术后辅助化疗的结果也不同。我们的数据显示，早期食管癌微转移、精准判断术后辅助治疗的获益人群及发现新的有效辅助治疗手段应该成为食管癌诊治的研究热点。</p><p>关键词 :食管癌，食管癌切除术，术后复发，无进展生存，辅助化疗</p><disp-formula id="hanspub.36416-formula5"><graphic xlink:href="//html.hanspub.org/file/10-1571381x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2020 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/10-1571381x8_hanspub.png" /> <img src="//html.hanspub.org/file/10-1571381x9_hanspub.png" /></p></sec><sec id="s3"><title>1. 引言</title><p>食管癌是我国常见的消化道恶性肿瘤，发病率位居第6位，但死亡率位居第4位，严重威胁着国民健康 [<xref ref-type="bibr" rid="hanspub.36416-ref1">1</xref>] [<xref ref-type="bibr" rid="hanspub.36416-ref2">2</xref>]。我国食管癌常见的病理类型为鳞状细胞癌，临床诊疗指南推荐可手术食管癌病人接受以手术切除为主的综合治疗，但临床数据显示，部分进展期患者对现有的治疗反应不佳，术后病理显示淋巴结转移阳性时预示患者生存差 [<xref ref-type="bibr" rid="hanspub.36416-ref3">3</xref>]。术后无进展生存分析可以了解真实世界中食管癌的转归特点、反应患者疾病复发特点及患者对辅助治疗的反应。但多数食管癌术后生存研究是基于总发病人数的生存分析，专门关注复发人群生存特点的研究较少。因此，我们回顾分析了近年来我院胸段食管癌术后复发的患者，分析其术后无进展生存时间特点及与临床分期、辅助治疗的关系，为阐明真实世界中胸部食管癌患者术后的疾病转归特点提供证据。</p></sec><sec id="s4"><title>2. 材料与方法</title><sec id="s4_1"><title>2.1. 研究人群</title><p>经医院伦理委员会批准，回顾性收集我院2008年1月至2015年12月就诊的食管癌术后复发患者，入选标准包括：胸段食管癌；接受食管癌切除手术、上下残端阴性、清扫淋巴结 ≥ 16枚；术后辅助治疗信息完备。排除标准：同时或顺时罹患其它恶性肿瘤者；术前接受抗肿瘤治疗者；非肿瘤因素死亡者。</p></sec><sec id="s4_2"><title>2.2. 临床特点及随访</title><p>术后2年内随访要求每3 (&#177;1)个月复查胸部及上腹CT、食管造影，用于判断局域淋巴结状况及吻合口状况；术后2~5年内随访要求每6个月复查胸部及上腹CT、食管造影，用于判断局域淋巴结状况及吻合口状况。根据病理报告，参照NCCN第8版食管癌TNM分期标准分期 [<xref ref-type="bibr" rid="hanspub.36416-ref4">4</xref>]。术后无进展生存时间定义为手术后至随访发现肿瘤复发时或疾病进展时。辅助化疗定义为术后接受过 ≥ 1次的含铂联合化疗。</p></sec><sec id="s4_3"><title>2.3. 统计</title><p>使用SPSS 19.0软件对数据进行统计，分析患者不同亚组间术后中位无进展生存时间及生存率的差异。其中两组间术后中位无进展生存时间差异采用t检验，多组间术后中位无进展生存时间差异采用one-way ANOVA，生存率的差异采用卡方检验。相关性分析采用Pearson相关系数分析。设定p值小于0.05为差异具备统计学意义。</p></sec></sec><sec id="s5"><title>3. 结果</title><p>我们收集并分析了我院8年间接受胸段食管癌切除并复发的706例患者的临床数据，其中鳞癌所占比例为93.06%，显著高于其它病理类型(表1所见)；总的1年、3年、5年术后无进展生存率为52.1%、14.4%、5.2%，1年、3年、5年总生存率为63.9%、39.9%、14.9%，术后无进展生存时间与术后总生存时间呈正相关(Pearson相关系数分析，r = 0.094，p = 0.02)。不同病理类型患者的中位术后无进展生存时间，鳞癌患者为13个月，腺癌14.5个月，小细胞癌12个月，其它14个月，各组间无统计学差异。</p><p>657例鳞癌患者中，根据pTNM分期分组，患者的术后无进展生存时间为3.41~26.4个月，3年术后无进展生存率为4.21~44.5%，5年术后无进展生存率为0~26.7%，术后无进展生存时间与pTNM分期呈负相关(表2所见)。</p><p>根据是否接受了辅助化疗来区分亚组，I期至IIa期患者接受辅助化疗对术后无进展生存期影响不明显(表3所见)；IIb期患者无论是否存在淋巴结转移，接受辅助化疗的获益也不明显(表3所见)；III期患者接受辅助化疗对术后无进展生存期改善明显，差异有统计学意义(表4所见)。</p></sec><sec id="s6"><title>4. 讨论</title><p>近年来食管癌的发病率趋于平缓下降，但死亡率仍较高，反映出目前食管癌的治疗手段存在不足。我们分析了我中心复发的胸部食管癌手术后无进展生存的状态，描述了不同TNM分期、不同病理分型术后无病生存的特点，并分析了不同TNM分期辅助化疗对术后无进展生存时间的影响，为食管癌术后精准管理提供了证据。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Clinical characteristics in this stud</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  colspan="2"   rowspan="2"  >Category</th><th align="center" valign="middle"  colspan="6"  >Subgroup</th></tr></thead><tr><td align="center" valign="middle" >Squamous cell carcinoma</td><td align="center" valign="middle" >Adenocarcinoma</td><td align="center" valign="middle"  colspan="2"  >Small cell carcinoma</td><td align="center" valign="middle"  colspan="2"  >Others</td></tr><tr><td align="center" valign="middle"  colspan="2"  >Patients (n, %)</td><td align="center" valign="middle" >657,93.06</td><td align="center" valign="middle" >14,1.98</td><td align="center" valign="middle"  colspan="2"  >19,2.69</td><td align="center" valign="middle"  colspan="2"  >16,2.27</td></tr><tr><td align="center" valign="middle"  colspan="2"  >Age (y, mean &#177; SD)</td><td align="center" valign="middle" >58.11 &#177; 7.47</td><td align="center" valign="middle" >58.71 &#177; 7.14</td><td align="center" valign="middle"  colspan="2"  >60.78 &#177; 7.04</td><td align="center" valign="middle"  colspan="2"  >57.68 &#177; 7.07</td></tr><tr><td align="center" valign="middle"  colspan="2"  >Gender (n)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle"  colspan="2"  ></td><td align="center" valign="middle"  colspan="2"  ></td></tr><tr><td align="center" valign="middle"  colspan="2"  >Male:Female</td><td align="center" valign="middle" >498:159</td><td align="center" valign="middle" >11:3</td><td align="center" valign="middle"  colspan="2"  >13:6</td><td align="center" valign="middle"  colspan="2"  >13:3</td></tr><tr><td align="center" valign="middle"  colspan="2"  >Thoracic site (n)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle"  colspan="2"  ></td><td align="center" valign="middle"  colspan="2"  ></td></tr><tr><td align="center" valign="middle"  colspan="2"  >Upper</td><td align="center" valign="middle" >75</td><td align="center" valign="middle" >0</td><td align="center" valign="middle"  colspan="2"  >2</td><td align="center" valign="middle"  colspan="2"  >1</td></tr><tr><td align="center" valign="middle"  colspan="2"  >Middle</td><td align="center" valign="middle" >456</td><td align="center" valign="middle" >7</td><td align="center" valign="middle"  colspan="2"  >16</td><td align="center" valign="middle"  colspan="2"  >9</td></tr><tr><td align="center" valign="middle"  colspan="2"  >Lower</td><td align="center" valign="middle" >126</td><td align="center" valign="middle" >7</td><td align="center" valign="middle"  colspan="2"  >1</td><td align="center" valign="middle"  colspan="2"  >6</td></tr><tr><td align="center" valign="middle"  colspan="3"  >Surgical procedures (n)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle"  colspan="2"  ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Sweet</td><td align="center" valign="middle"  colspan="2"  >592</td><td align="center" valign="middle" >13</td><td align="center" valign="middle"  colspan="2"  >16</td><td align="center" valign="middle"  colspan="2"  >16</td></tr><tr><td align="center" valign="middle" >Ivor-Lowis</td><td align="center" valign="middle"  colspan="2"  >29</td><td align="center" valign="middle" >1</td><td align="center" valign="middle"  colspan="2"  >2</td><td align="center" valign="middle"  colspan="2"  >0</td></tr><tr><td align="center" valign="middle" >McKeown</td><td align="center" valign="middle"  colspan="2"  >35</td><td align="center" valign="middle" >0</td><td align="center" valign="middle"  colspan="2"  >1</td><td align="center" valign="middle"  colspan="2"  >0</td></tr><tr><td align="center" valign="middle" >pTNM stages (n)</td><td align="center" valign="middle"  colspan="2"  ></td><td align="center" valign="middle" ></td><td align="center" valign="middle"  colspan="2"  ></td><td align="center" valign="middle"  colspan="2"  ></td></tr><tr><td align="center" valign="middle" >Ia</td><td align="center" valign="middle"  colspan="2"  >18</td><td align="center" valign="middle" >2</td><td align="center" valign="middle"  colspan="2"  >2</td><td align="center" valign="middle"  colspan="2"  >1</td></tr><tr><td align="center" valign="middle" >Ib</td><td align="center" valign="middle"  colspan="2"  >34</td><td align="center" valign="middle" >1</td><td align="center" valign="middle"  colspan="2"  >4</td><td align="center" valign="middle"  colspan="2"  >2</td></tr><tr><td align="center" valign="middle" >IIa</td><td align="center" valign="middle"  colspan="2"  >84</td><td align="center" valign="middle" >0</td><td align="center" valign="middle"  colspan="2"  >0</td><td align="center" valign="middle"  colspan="2"  >1</td></tr><tr><td align="center" valign="middle" >IIb</td><td align="center" valign="middle"  colspan="2"  >238</td><td align="center" valign="middle" >3</td><td align="center" valign="middle"  colspan="2"  >8</td><td align="center" valign="middle"  colspan="2"  >5</td></tr><tr><td align="center" valign="middle" >IIIa</td><td align="center" valign="middle"  colspan="2"  >152</td><td align="center" valign="middle" >2</td><td align="center" valign="middle"  colspan="2"  >2</td><td align="center" valign="middle"  colspan="2"  >2</td></tr><tr><td align="center" valign="middle" >IIIb</td><td align="center" valign="middle"  colspan="2"  >72</td><td align="center" valign="middle" >0</td><td align="center" valign="middle"  colspan="2"  >3</td><td align="center" valign="middle"  colspan="2"  >4</td></tr><tr><td align="center" valign="middle" >IIIc</td><td align="center" valign="middle"  colspan="2"  >48</td><td align="center" valign="middle" >6</td><td align="center" valign="middle"  colspan="2"  >0</td><td align="center" valign="middle"  colspan="2"  >1</td></tr><tr><td align="center" valign="middle" >IV</td><td align="center" valign="middle"  colspan="2"  >11</td><td align="center" valign="middle" >0</td><td align="center" valign="middle"  colspan="2"  >0</td><td align="center" valign="middle"  colspan="2"  >0</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr></tbody></table></table-wrap><p>表1. 患者一般状况</p><p>m, median; %, percent; PFS, progression free survival; y, year; SD, standard deviation; Sweet, Sweet esophagectomy; Ivor-Lowis, Ivor-Lowis esophagectomy; McKeown, McKeown esophagectomy.</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Post-operative PFS in patients with sub-stages of pTN</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >Ia</th><th align="center" valign="middle" >Ib</th><th align="center" valign="middle" >IIa</th><th align="center" valign="middle" >IIb</th><th align="center" valign="middle" >IIIa</th><th align="center" valign="middle" >IIIb</th><th align="center" valign="middle" >IIIc</th><th align="center" valign="middle" >IV</th><th align="center" valign="middle" >P</th></tr></thead><tr><td align="center" valign="middle" >Number</td><td align="center" valign="middle" >18</td><td align="center" valign="middle" >34</td><td align="center" valign="middle" >84</td><td align="center" valign="middle" >238</td><td align="center" valign="middle" >152</td><td align="center" valign="middle" >72</td><td align="center" valign="middle" >48</td><td align="center" valign="middle" >11</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >PFS (m, mouth)</td><td align="center" valign="middle" >16.1</td><td align="center" valign="middle" >26.4</td><td align="center" valign="middle" >19.3</td><td align="center" valign="middle" >14</td><td align="center" valign="middle" >12.2</td><td align="center" valign="middle" >7.32</td><td align="center" valign="middle" >8.93</td><td align="center" valign="middle" >3.41</td><td align="center" valign="middle" >&lt;0.0001</td></tr><tr><td align="center" valign="middle" >3-year PFS (%)</td><td align="center" valign="middle" >33.9</td><td align="center" valign="middle" >44.5</td><td align="center" valign="middle" >30.1</td><td align="center" valign="middle" >15.1</td><td align="center" valign="middle" >9.8</td><td align="center" valign="middle" >4.21</td><td align="center" valign="middle" >8.27</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >&lt;0.0001</td></tr><tr><td align="center" valign="middle" >5-year PFS (%)</td><td align="center" valign="middle" >11.4</td><td align="center" valign="middle" >26.7</td><td align="center" valign="middle" >11.7</td><td align="center" valign="middle" >6.71</td><td align="center" valign="middle" >2.65</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >5.15</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >&lt;0.0001</td></tr></tbody></table></table-wrap><p>表2. 不同TNM分期的术后疾病无进展生存状况</p><p>m, median; %, percent; PFS, progression free survival.</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> The effect of PFS with adjuvant chemotherapy in I-II patient</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle"  colspan="2"  >I-IIa</th><th align="center" valign="middle" ></th><th align="center" valign="middle"  colspan="2"  >IIb/N−</th><th align="center" valign="middle"  colspan="2"  >IIb/N+</th><th align="center" valign="middle" ></th></tr></thead><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >AD</td><td align="center" valign="middle" >Un-AD</td><td align="center" valign="middle" >P</td><td align="center" valign="middle" >AD</td><td align="center" valign="middle" >Un-AD</td><td align="center" valign="middle" >AD</td><td align="center" valign="middle" >Un-AD</td><td align="center" valign="middle" >P</td></tr><tr><td align="center" valign="middle" >Number</td><td align="center" valign="middle" >46</td><td align="center" valign="middle" >85</td><td align="center" valign="middle"  rowspan="2"  >0.81</td><td align="center" valign="middle" >84</td><td align="center" valign="middle" >83</td><td align="center" valign="middle" >27</td><td align="center" valign="middle" >19</td><td align="center" valign="middle"  rowspan="2"  >0.61</td></tr><tr><td align="center" valign="middle" >PFS (m, mouth)</td><td align="center" valign="middle" >22.1</td><td align="center" valign="middle" >20.1</td><td align="center" valign="middle" >15.2</td><td align="center" valign="middle" >12</td><td align="center" valign="middle" >13.9</td><td align="center" valign="middle" >20.1</td></tr></tbody></table></table-wrap><p>表3. 辅助化疗对I~II期食管癌患者疾病无进展生存的影响</p><p>m, median; AD, adjuvant chemotherapy; Un-AD, no adjuvant chemotherapy; N−, lymph node metastasis negative; N+, lymph node metastasis positive; PFS, progression free survival.</p><table-wrap id="table4" ><label><xref ref-type="table" rid="table4">Table 4</xref></label><caption><title> The effect of PFS with adjuvant chemotherapy in III patient</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle"  colspan="2"  >IIIa/N−</th><th align="center" valign="middle"  colspan="2"  >IIIa/N+</th><th align="center" valign="middle" ></th><th align="center" valign="middle"  colspan="2"  >IIIb</th><th align="center" valign="middle" ></th><th align="center" valign="middle"  colspan="2"  >IIIc</th><th align="center" valign="middle" ></th></tr></thead><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >AD</td><td align="center" valign="middle" >Un-AD</td><td align="center" valign="middle" >AD</td><td align="center" valign="middle" >Un-AD</td><td align="center" valign="middle" >P</td><td align="center" valign="middle" >AD</td><td align="center" valign="middle" >Un-AD</td><td align="center" valign="middle" >P</td><td align="center" valign="middle" >AD</td><td align="center" valign="middle" >Un-AD</td><td align="center" valign="middle" >P</td></tr><tr><td align="center" valign="middle" >Number</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >72</td><td align="center" valign="middle" >48</td><td align="center" valign="middle"  rowspan="2"  >0.0009</td><td align="center" valign="middle" >38</td><td align="center" valign="middle" >21</td><td align="center" valign="middle"  rowspan="2"  >&lt;0.0001</td><td align="center" valign="middle" >21</td><td align="center" valign="middle" >18</td><td align="center" valign="middle"  rowspan="2"  >0.047</td></tr><tr><td align="center" valign="middle" >PFS (m, mouth)</td><td align="center" valign="middle" >20</td><td align="center" valign="middle" >9</td><td align="center" valign="middle" >15.2</td><td align="center" valign="middle" >5.75</td><td align="center" valign="middle" >11.1</td><td align="center" valign="middle" >1.9</td><td align="center" valign="middle" >9.32</td><td align="center" valign="middle" >2.68</td></tr></tbody></table></table-wrap><p>表4. 辅助化疗对III期食管癌患者疾病无进展生存的影响</p><p>m, median; AD, adjuvant chemotherapy; Un-AD, no adjuvant chemotherapy; N−, lymph node metastasis negative; N+, lymph node metastasis positive; PFS, progression free survival.</p><p>研究人群中占比重最大的是局部进展期患者，这种特点与以往的报道相符 [<xref ref-type="bibr" rid="hanspub.36416-ref5">5</xref>]。在我们的研究中，早期食管癌术后复发患者(I~IIa)占20.7%，分析Ia期患者术后中位无进展生存时间为16.1个月，生存状况不及Ib期患者和IIa期患者。这种状况说明部分食管癌患者早期即可能存在远处微转移，导致术后很早便出现复发 [<xref ref-type="bibr" rid="hanspub.36416-ref6">6</xref>] [<xref ref-type="bibr" rid="hanspub.36416-ref7">7</xref>] [<xref ref-type="bibr" rid="hanspub.36416-ref8">8</xref>] [<xref ref-type="bibr" rid="hanspub.36416-ref9">9</xref>]。既往研究发现，食管的淋巴引流特点使得部分食管癌细胞有机会在病变侵及黏膜下层后便出现纵膈外淋巴结转移 [<xref ref-type="bibr" rid="hanspub.36416-ref10">10</xref>] [<xref ref-type="bibr" rid="hanspub.36416-ref11">11</xref>]，手术清扫范围不充分，则这些患者会很早出现复发。但是术前准确判断淋巴结转移的方法尚不能满足临床需要 [<xref ref-type="bibr" rid="hanspub.36416-ref12">12</xref>] [<xref ref-type="bibr" rid="hanspub.36416-ref13">13</xref>]，判断微转移的方法更是乏善可陈。我们的数据提醒研究者，应该重视早期患者的精准分期，减少早期患者术后迅速复发的发生。</p><p>晚期患者(IIIb~IV)术后的中位无进展生存时间为3.41~8.93个月，IV期患者术后1年无进展生存率为0%；晚期患者接受辅助化疗后可以显著改善术后中位无进展生存时间。相反，在早期患者(I~Ib)术后辅助化疗并不能使患者生存获益，甚至会让患者(IIb)生存受损。我们的数据说明了辅助化疗在晚期食管癌术后的治疗价值，但值得注意的是辅助化疗对生存的改善尚不能让人满意，早期患者术后辅助治疗存疑 [<xref ref-type="bibr" rid="hanspub.36416-ref14">14</xref>] [<xref ref-type="bibr" rid="hanspub.36416-ref15">15</xref>]，临床期待新辅助治疗方法的加入。近年来大量临床实验数据说明了免疫检查点PD-1抑制剂对晚期食管癌治疗有效 [<xref ref-type="bibr" rid="hanspub.36416-ref3">3</xref>]，因此，术后辅助PD-1抑制剂的疗效值得期待。</p><p>总之，我们的回顾性数据描述了胸部食管癌术后无进展生存的特点，这些数据提醒我们，早期食管癌微转移、精准判断术后辅助治疗的获益人群及发现新的有效辅助治疗手段应该成为食管癌诊治的研究热点。</p></sec><sec id="s7"><title>文章引用</title><p>刘鸿章,陈 新,何 明,高占杰,李 丹,李欣慧,张香梅,赵继东,晏 峰. 706例胸段食管癌患者术后无进展生存状况分析Analysis of Post-Esophagectomy Progression Free Survival in 706 Patients with Thoracic Esophageal Carcinoma[J]. 临床医学进展, 2020, 10(07): 1199-1204. https://doi.org/10.12677/ACM.2020.107184</p></sec><sec id="s8"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.36416-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">He, Y.T., Li, D.J., Shan, B.E., et al. (2019) Incidence and Mortality of Esophagus Cancer in China, 2008-2012. Chinese Journal of Cancer Research, 31, 426-434. &lt;br&gt;https://doi.org/10.21147/j.issn.1000-9604.2019.03.04</mixed-citation></ref><ref id="hanspub.36416-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Chen, W.Q., Zheng, R.S., Zhang, S.W., et al. (2017) Cancer Incidence and Mortality in China, 2013. Cancer Letters, 401, 63-71. &lt;br&gt;https://doi.org/10.1016/j.canlet.2017.04.024</mixed-citation></ref><ref id="hanspub.36416-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">中国临床肿瘤学会(CSCO)食管癌专委会. 2020CSCO食管癌诊疗指南[Z]. 北京: 中国临床肿瘤学会(CSCO)食管癌专委会.</mixed-citation></ref><ref id="hanspub.36416-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">D’Journo, X.B. (2018) Clinical Implication of the Innovations of the 8(th) Edition of the TNM Classification for Esophageal and Esophago-Gastric Cancer. Journal of Thoracic Disease, 10, S2671-S2681.  
&lt;br&gt;https://doi.org/10.21037/jtd.2018.03.182</mixed-citation></ref><ref id="hanspub.36416-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">毛友生, 高树庚, 王群, 等. 中国食管癌临床流行特征及外科治疗概况大数据分析[J]. 中华肿瘤杂志, 2020(3): 228-233.</mixed-citation></ref><ref id="hanspub.36416-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Shaheen, O., Ghibour, A. and Alsaid, B. (2017) Esophageal Cancer Metastases to Unexpected Sites: A Systematic Review. Gastroenterology Research and Practice, 2017, Article ID: 1657310. &lt;br&gt;https://doi.org/10.1155/2017/1657310</mixed-citation></ref><ref id="hanspub.36416-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Akutsu, Y., Kato, K., Igaki, H., et al. (2016) The Prevalence of Overall and Initial Lymph Node Metastases in Clinical T1N0 Thoracic Esophageal Cancer: From the Results of JCOG0502, a Prospective Multicenter Study. Annals of Surgery, 264, 1009-1015. &lt;br&gt;https://doi.org/10.1097/SLA.0000000000001557</mixed-citation></ref><ref id="hanspub.36416-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Liu, J., Liu, Q., Wang, Y., et al. (2016) Nodal Skip Metastasis Is Associated with a Relatively Poor Prognosis in Thoracic Esophageal Squamous Cell Carcinoma. European Journal of Surgical Oncology, 42, 1202-1205.  
&lt;br&gt;https://doi.org/10.1016/j.ejso.2016.05.025</mixed-citation></ref><ref id="hanspub.36416-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">He, S.-L., Yang, Y.-S., Wang, W.-P., et al. (2019) Prognostic Evaluation of Nodal Skip Metastasis for Thoracic Esophageal Squamous Cell Carcinoma. The Annals of Thoracic Surgery, 108, 1717-1723.  
&lt;br&gt;https://doi.org/10.1016/j.athoracsur.2019.03.081</mixed-citation></ref><ref id="hanspub.36416-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Wang, Y., Zhu, L., Xia, W. and Wang, F. (2018) Anatomy of Lymphatic Drainage of the Esophagus and Lymph Node Metastasis of Thoracic Esophageal Cancer. Cancer Management and Research, 10, 6295-6303.  
&lt;br&gt;https://doi.org/10.2147/CMAR.S182436</mixed-citation></ref><ref id="hanspub.36416-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">李辉, 章智荣. 食管癌根治术淋巴结清扫的争议与共识[J]. 中华消化外科杂志, 2019(1): 39-42.</mixed-citation></ref><ref id="hanspub.36416-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Wu, H.R., et al. (2019) Analysis on CT in Diagnosis of Lymph Node Metastasis of Thoracic Esophageal Cancer with Minimum Diameter Greater than 1 cm. Zhonghua Wai Ke Za Zhi, 57, 601-606.</mixed-citation></ref><ref id="hanspub.36416-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Goense, L., Meziani, J., van Rossum, P.S.N., et al. (2018) Limited Additional Value of Cervical Ultrasonography over a Negative 18F-FDG PET/CT for Diagnosing Cervical Lymph Node Metastases in Patients with Esophageal Cancer: A Systematic Review and Meta-Analysis. Nuclear Medicine Communications, 39, 645-651.  
&lt;br&gt;https://doi.org/10.1097/MNM.0000000000000847</mixed-citation></ref><ref id="hanspub.36416-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">黄泽凯, 李少雷, 鲁方亮, 等. 术后治疗能否给已行TP方案新辅助化疗的局部进展期食管鳞状细胞癌患者带来生存获益?[J]. 中国胸心血管外科临床杂志, 2019, 26(5): 413-418.</mixed-citation></ref><ref id="hanspub.36416-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">张杰, 陈海泉, 张亚伟, 等. 食管癌术后辅助化疗的荟萃分析和来自复旦大学附属肿瘤医院的配对研究[J]. 中国癌症杂志, 2008(4): 276-281.</mixed-citation></ref></ref-list></back></article>